User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

7818

Interactions with Platform & by Email *

INTERACTIONS

1093

Unique # Participated *

PARTICIPANTS

233

Responses Validated *

VALIDATIONS

44

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Therapeutics.....I-3
  
   Cancer.....I-4
Other Therapeutic Mabs.....I-4
Diagnostics.....I-4
  
   Worldwide MAb-Based Products Market: A Profile.....II-1
MAb Market – Set for Significant Growth.....II-1
1$100
   Therapeutic mAb Market – Principal Driving Force.....II-2
Development of New MAbs on a Fast Track.....II-2
1$100
   Genomics Research Leads Way to New Monoclonal Antibodies.....II-3
Bright Outlook for MAbs.....II-3
Current and Future Analysis.....II-3
Regional Perspective.....II-3
1$100
   Product Segment Perspective.....II-4
Competitive Scenario.....II-4
Intensifying Consolidation Activity.....II-4
1$100
   Table 1: Major Acquisitions of Antibody-Focused Companies (2005-2007).....II-5

Table 2: Leading Players in the Worldwide Monoclonal Antibody Therapy Market (2005): Percentage Breakdown of Sales for Genentech/Roche, J & J/Schering Plough, Abbott Laboratories, MedImmune, ImClone/BMS, and Eli Lilly (includes corresponding Graph/Chart).....II-5
1$300
   Table 3: Leading Drugs in the Global Therapeutic Monoclonal Antibodies Market (2006): Percentage Breakdown of Dollar Sales for Remicade, Rituxan, Herceptin, Avastin, Humira, Erbitux, Synagis, Xolair and Others (includes corresponding Graph/Chart).....II-6

Table 4: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Manufacturers by Sales for Genentech, Johnson & Johnson, Roche, Abbott, MedImmune, Schering Plough, Eli Lilly, and Others (includes corresponding Graph/Chart).....II-6

Table 5: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Drugs by Sales for Remicade, Rituxan, Herceptin, Synagis, Humira, Avastin, ReoPro, Erbitux, Xolair, and Others (includes corresponding Graph/Chart).....II-6
1$300
   Table 6: Leading Products in the Global Oncology Monoclonal Antibodies Market (2008E): Percentage Share Breakdown of Sales for Avastin, Herceptin, Rituxan, Erbitux, and Others (includes corresponding Graph/Chart).....II-7

Table 7: Leading Products in the Global Antibody-Based Anti-Inflammatory Market (2006): Percentage Share Breakdown of Revenues for Enbrel, Remicade, Humira, and Others (includes corresponding Graph/Chart).....II-7
Therapeutic Antibodies in the Market.....II-7
1$300
   Drug Developers Trying to Break the Shackles.....II-8
Rituximab Vs. Epratuzumab.....II-8
1$100
   A Revolution Not too Far.....II-9
Milestones in Development of MAbs.....II-9
Focus on Unmet Medical Needs in the Emerging Markets.....II-9
1$100
   Evolution of Monoclonal Antibodies – A Historical Journey.....II-101$100
   Trends and Issues.....II-11
Shift Towards Humanized and Fully Human Antibodies.....II-11
Ageing Baby Boomers Spur MAbs Growth.....II-11
Non-Existent Generic Competition Favors MAb Market.....II-11
1$100
   Partnerships and Collaborations Spark Increase in Profit Margins.....II-12
Pharma Majors & CMOs Augment Investment in Mab Production.....II-12
Rising Number of MAbs Under Clinical Trials.....II-12
1$100
   Select Clinical Trials for Monoclonal Antibodies.....II-131$100
   Major Monoclonal Antibodies in Phase III Trials Across the World.....II-14
High Costs Impede MAbs Penetration.....II-14
1$100
   Opportunities in Technology Development.....II-15
Advancements & Challenges in Antibody Production Processes.....II-15
Increasing Demand for Protein A in Mab Manufacturing.....II-15
1$100
   FCA- A Major Cause for Discomfort in Mice.....II-16
Innovations to Drive Growth in Anti-Ovarian Cancer Drugs Market.....II-16
Rising Incidence of NHL to Drive Monoclonal Antibody Drug Market.....II-16
1$100
   Immune System: Natural Defenders.....II-17
Human Antibodies.....II-17
Antibodies Offer Natural Immunity.....II-17
Induction of The Immune Process.....II-17
Mechanism of Action.....II-17
1$100
   Polyclonal and Monoclonal Antibodies.....II-18
Production of Monoclonal Antibodies.....II-18
Traditional Methods.....II-18
The Hybridoma Technology.....II-18
Separation and Purification of Monoclonals.....II-18
1$100
   Factors Impacting Production of MAbs.....II-19
Types of Monoclonal Antibodies.....II-19
Table 8: Worldwide MAb Market by Product Type (2008): Percentage Share Breakdown for Chimeric, Humanized, Human and Murine (includes corresponding Graph/Chart).....II-19
Murine Monoclonal Antibodies.....II-19
1$300
   Humanized Antibodies/ CDR Grafted Antibodies.....II-20
Murine Vs Human Monoclonal Antibodies.....II-20
1$100
   Chimeric Antibodies: Show Lesser Antigenicity.....II-21
Fully Human Antibodies.....II-21
Bispecific Antibodies.....II-21
Certain Limitations Do Exist.....II-21
1$100
   Advantages of MAbs.....II-22
Advantages and Limitations of MAb Technologies.....II-22
1$100
   Monoclonal Antibody Based Diagnostics.....II-23
Immunodiagnostics.....II-23
Monoclonals Used as Targeting Agents.....II-23
Radio labeled Monoclonal Antibodies for Diagnostic Imaging.....II-23
1$100
   The Pros and Cons of MAb-Based Immunoconjugates.....II-24
Cytogen: The First to Introduce A Monoclonal Antibody-based Cancer Agent.....II-24
NeoProbe’s Radioimmunogzuided Surgery.....II-24
1$100
   Cancer.....II-25
A Historical Overview.....II-25
Initial Hiccups.....II-25
Tumor Markers.....II-25
1$100
   Evolution of Therapeutic Antibody Products.....II-26
Advantages of Therapeutic Monoclonal Antibodies.....II-26
1$100
   Current Scenario in Monoclonal Antibody Therapeutics Market.....II-27
Table 9: Monoclonal Antibody Market by Therapy Area (2004 & 2010): Percentage Breakdown by Sales for Oncology, Arthritis, Immune & Inflammatory Disorders, Infectious Diseases, Cardiovascular, Respiratory, Ophthalmology, and CNS (includes corresponding Graph/Chart).....II-27
1$300
   Cancer Therapeutics.....II-28
Monoclonal Antibodies Offer Hope Against Cancer.....II-28
Monoclonal Antibodies Approved For Cancer Treatment in the World.....II-28
1$100
   Monoclonal Antibody Cancer Therapies Under Development.....II-29
Antibody Therapies for Cancer.....II-29
1$100
   Cancer: A Serious Issue and Plaguing Illness Worldwide.....II-30
Breast Cancer: The Most Common Form of Cancer in American Women.....II-30
Breast Cancer - Treatment Options.....II-30
1$100
   Monoclonal Antibodies Against NHL.....II-31
Monoclonal Antibodies Against Ovarian Cancer.....II-31
MAb Immunotherapy – Effective for Residual Ovarian Cancer.....II-31
Melanoma.....II-31
1$100
   Immunologic Effector Functions.....II-32
Colorectal Cancer: Rising Incidence.....II-32
Panorex: The First Cancer Therapeutic in the Market.....II-32
Myeloid Leukemia.....II-32
2$200
   Therapeutic Monoclonal Antibody Drugs and Applications.....II-34
MAbs used in Clinical Field.....II-34
Inflammation Therapeutics.....II-34
Inflammation.....II-34
1$100
   Asthma: A Chronic Affliction.....II-35
Autoimmune Diseases.....II-35
What Goes Wrong.....II-35
1$100
   Intervention Better Than Prevention.....II-36
Some Autoimmune Diseases.....II-36
Multiple Sclerosis.....II-36
1$100
   Crohn’s Disease.....II-37
Rheumatoid Arthritis.....II-37
Organ Transplantation.....II-37
Biology of Transplantation.....II-37
Types of Transplants.....II-37
Autografts.....II-37
1$100
   Syngeneic Transplants.....II-38
Allografts.....II-38
Xenografts.....II-38
Follow-up Treatment.....II-38
Products to Counter Rejection.....II-38
OKT3: A Monoclonal Already in the Market.....II-38
1$100
   Infectious Diseases.....II-39
Sepsis .....II-39
A Rapid Process.....II-39
Gram Negative Bacteria are the Causative Agents.....II-39
1$100
   A Retrospect.....II-40
Monoclonal Antibodies and Septic Shock.....II-40
HIV/AIDS.....II-40
What is AIDS?.....II-40
1$100
   Global Statistics.....II-41
HIV/AIDS Testing.....II-41
Monoclonal Antibodies and HIV.....II-41
Cardiovascular.....II-41
Cardiovascular Diseases are Fatal.....II-41
1$100
   Treatment Options.....II-42
Causes of Cardiovascular Diseases.....II-42
ReoPro.....II-42
1$100
   Regulations in the US.....II-43
Approval: A Laborious Process.....II-43
Clinical Trials.....II-43
1$100
   Orphan Drug Status.....II-44
1$100
   Rituxan and Herceptin from Genentech.....II-45
FuCell hybridomas.....II-45
Test-tube MAbs/ Phase Display Library.....II-45
Rituxan for Cancer Treatment.....II-45
1$100
   GenMAb Develops Fully Human Antibodies.....II-46
Protein Design Labs Licenses Trioma.....II-46
Protein Design Labs’ Innovative Technology.....II-46
1$100
   Amgen Introduces Vectibix.....II-47
Trevigen Introduces Mouse Monoclonal Antibody.....II-47
UCB Receives FDA Approval for Cimzia®.....II-47
GSK’s Tykerb Receives FDA Approval.....II-47
1$100
   Dr. Reddy’s Introduces Reditux™.....II-48
Morphotek Receives Orphan Drug Status for MORAb - 009 mAb.....II-48
Biocon Introduces BIOMab Monoclonal Antibody.....II-48
Biotest AG and AERES Biomedical Develop BT-062.....II-48
Genentech Launches Avastin.....II-48
Biotest Unveils Intratect®.....II-48
1$100
   Genentech Introduces Xolair.....II-49
Genentech Unveils Raptiva.....II-49
Corixa Presents BEXXAR.....II-49
IGEN Launches Monoclonal Antibody Therapies.....II-49
MAb Against Pseudomonas Aeruginosa.....II-49
Wyeth Introduces Mylotarg.....II-49
1$100
   EUSA Pharma to Take Over Cytogen.....II-50
AVANIR Inks a Definitive Agreement to Divest Anthrax Antibodies.....II-50
1$100
   Access Pharmaceuticals Acquires Somanta Pharmaceuticals.....II-51
Daiichi Sankyo to Take Over U3 Pharma.....II-51
IMUC Completes Molecular Antibody Technology Acquisition.....II-51
Callisto Merger Corporation Merges with Celldex Therapeutics.....II-51
1$100
   Genmab Enters into Antibody Research Collaboration with Pepscan.....II-52
BTI Enters into an Agreement with Raven.....II-52
Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104.....II-52
1$100
   Eusa Sells Antibody Research Business.....II-53
CG Therapeutics and UoW Agree for Joint Monoclonal Antibody Program.....II-53
Raven and CMC ICOS Collaborate to Advance RAV18.....II-53
SDI to Develop mAbs for SAIC-F and NCI.....II-53
1$100
   HGS Reacquires Rights for TRAIL Receptor Antibodies.....II-54
CAT Grants Exclusive Worldwide License of CAT-213 to iCo.....II-54
Morphotek and HMI in Licensing Agreement.....II-54
Amgen Enters into Licensing Agreement with Kyowa Hakko.....II-54
1$100
   Dyax and Sanofi-Aventis Sign Agreements.....II-55
HGS Enters into Antibody Collaboration Agreement with Xencor.....II-55
1$100
   CSL Limited Inks a Collaboration Agreement with Celltrion.....II-56
Eisai Acquires Morphotek.....II-56
1$100
   Astellas US Holding Takes Over Agensys.....II-57
Astrazeneca Creates New Integrated Business Unit – Medimmune.....II-57
1$100
   Genentech Acquires Tanox.....II-58
Biotest Acquires Assets of Nabi Biologics.....II-58
CMC Acquires ICOS Biologics Operation.....II-58
Roche Takes Over THP.....II-58
1$100
   GTC and LFB Commence CD20 Monoclonal Antibody Development.....II-59
Regeneron Grants a Non-Exclusive License to AstraZeneca.....II-59
OncoMed Enters into Monoclonal Antibody Deal with GSK.....II-59
1$100
   BioArctic and Eisai Announce Licensing Agreement.....II-60
MediGene Collaborates with Celltrion.....II-60
Amgen Inks Collaboration and License Pact with Daiichi Sankyo.....II-60
CMC Biopharmaceuticals Inks Agreement with Morphotek.....II-60
1$100
   CMC Biopharmaceuticals Inks Agreement with Biotest.....II-61
Eli Lilly Collaborates with MacroGenics.....II-61
Genentech Inks Global Licensing Agreement with Seattle Genetics.....II-61
VaxGen to Merge with Raven Biotechnologies.....II-61
1$100
   Abeome Enters into Distribution Agreement with Millipore.....II-62
Compugen Forays into Monoclonal Antibody Business.....II-62
MilleGen and LFB Enter into Partnership Agreement.....II-62
1$100
   Favrille Acquires Diversa’s Anti-CD20 Monoclonal Antibodies.....II-63
Kirin Inks Licensing Agreement with Astellas Pharma.....II-63
Viropro in Partnership with NRC-BRI.....II-63
1$100
   Merck Acquires Abmaxis.....II-64
Micromet Merges with CancerVax.....II-64
Tanabe & Janssen Team Up to Develop Anti-TNF Alpha Monoclonal Antibody.....II-64
Intercell Enters into Strategic Alliance with Kirin.....II-64
1$100
   Xencor Extends R&D Collaboration with Roche.....II-65
MedImmune Inks Licensing Agreement with Japan Tobacco.....II-65
Immunomedics Enters into an Agreement with UCB for Epratuzumab.....II-65
1$100
   Akorn and Serum Institute Enter into Development and Distribution Agreement.....II-66
FDA Clears IND for CYT-500 Monoclonal Antibody from Cytogen.....II-66
LSP Acquires Global License for Monoclonal Antibodies from Ludwig Institute.....II-66
1$100
   Seattle Genetics in Agreement with Laureate to Manufacture Monoclonal Antibody Drug
  Candidates.....II-67
EU Grants Orphan Drug Designation to GPC’s Anticancer Monoclonal Antibody.....II-67
1$100
   Laureate Collaborates with Bradmer on Neuradiab Monoclonal Antibody for Cancer
  Treatment.....II-68
Amgen Takes Over Abgenix.....II-68
Celera and Medarex in Strategic Alliance for Developing Human Monoclonal Antibody
  Therapeutics.....II-68
UCB Collaborates with Immunomedics.....II-68
1$100
   Crucell Collaborates with DSM for Monoclonal Antibody Licensing Business.....II-69
Roche Licenses Rabbit Monoclonal Antibody Technology from Epitomics.....II-69
BioGenex Receives FDA Pre-Market Approval for InSite™ Monoclonal Antibody.....II-69
Upstate Bags Marketing Rights for Anti-ZAP-70 Monoclonal Antibody.....II-69
1$100
   XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin Monoclonal
  Antibodies.....II-70
HGS Bags Two-Phase Contract for ABthrax™ Mab from the US Government.....II-70
Medarex and PharmAthene Receive Funding for Development of Valortim™.....II-70
1$100
   UCB Collaborates with Millenium.....II-71
MorphoSys Acquires Two Antibody Technology Companies.....II-71
Tanabe Seiyaku and Remicade Sign Addendum.....II-71
Abgenix Receives Royalty from Human Genome.....II-71
Amgen Acquires Tularik.....II-71
Sunesis Pharmaceuticals Collaborates with Biogen Idec.....II-71
1$100
   H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM Biologics.....II-72
EMBL and Abnova Inks Collaboration Agreement.....II-72
AstraZeneca and CAT in Five-Year Strategic Alliance for Monoclonal Antibody
  Research.....II-72
UCB Acquires Celltech.....II-72
1$100
   ImmunoGen Signs Licensing Agreement with Biogen.....II-73
Lonza Inks MAbs Manufacturing and Supply Agreement with NovImmune.....II-73
Avanir and Peregrine Sign License Agreement.....II-73
BioVest Concludes Agreement with Bioventix.....II-73
Roche to Set Up Two Manufacturing Facilities in Switzerland.....II-73
XTL Biopharm Bags European patent for Human Monoclonal Anti Body.....II-73
1$100
   MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials.....II-74
Health Canada Approves HUMIRA.....II-74
1$100
   CAT Signs Licensing Agreement with Micromet.....II-75
CAT Enters into Agreement with Genzyme.....II-75
Medarex and Avlon Enter into Agreement.....II-75
Micromet, Enzon and CAT Sign Cross-License Agreement.....II-75
Xerion and CAT Enter into Agreement.....II-75
Genetastix and Nissho Enter into Agreement.....II-75
1$100
   InNexus and Corixa Enter into Agreement.....II-76
Abbott Collaborates with LigoCyte.....II-76
CAT Acquires Drug Royalty Corporation.....II-76
CAT and Amrad Join Hands for Research.....II-76
IDEC's Receives FDA Approval for Zevalin.....II-76
Medarex Enters into Research Alliance with Seattle Genetics.....II-76
1$100
   Dow, Epicyte and Centocor Join Forces to Develop Monoclonal Antibody.....II-77
Eos, Medarex and Biosite in Alliance for Cancer Treatment.....II-77
Imgenex forms Alliance with GMO.....II-77
CAT and Elan Enter into Strategic Alliance.....II-77
Bioinvent International Enters into Agreement with Novo Nordisk for Drug Discovery
  Research.....II-77
1$100
   Epicyte and Dow Chemical Enter into Agreement.....II-78
Rockland Announces the Completion of Laboratory Expansion.....II-78
Roche’s MAbThera Receives Approval in Japan.....II-78
Aviva Launches Manufacturing and Marketing Operations.....II-78
ICOS and Seattle Enters into Joint Development and Manufacturing Agreement.....II-78
Medarex and Corixa Team-up to Develop Human Monoclonal Antibodies.....II-78
Taisho Enters into Research Alliance with IDEC.....II-78
1$100
   PDL Signs Agreement with InterMune.....II-79
ProMetic Signs Agreement with Integrated Protein.....II-79
Medarex Signs Agreement with ZynloGenetics.....II-79
CAT Joins Hands with GD. Searle.....II-79
Medarex and MedImmune Enter into Antibody Research Agreement.....II-79
Lonza Signs Agreement with ImClone Systems.....II-79
1$100
   MedImmune and Alkermes Enter into Agreement.....II-80
GTC and Abgenix Enter into Production Agreement.....II-80
Genzyme Transgenics Expands Agreement with Centocor.....II-80
PDL and InterMune Enter into an Agreement.....II-80
1$100
   Amgen, Inc. (US).....II-81
BD Biosciences (US).....II-81
1$100
   Biogen Idec Inc (US).....II-82
Biotest AG (Germany).....II-82
1$100
   CMC ICOS Biologics, Inc......II-83
Dendreon Corporation (US).....II-83
Elan Corporations Plc (Ireland).....II-83
1$100
   Eli Lilly and Company (US).....II-84
Genentech, Inc. (US).....II-84
1$100
   Human Genome Sciences, Inc. (US).....II-85
Immunomedics, Inc. (US).....II-85
1$100
   Johnson & Johnson (US).....II-86
Centocor (US).....II-86
1$100
   Ortho Biotech Products, L.P. (US).....II-87
Medarex, Inc. (US).....II-87
MedImmune, Inc. (US).....II-87
1$100
   PDL BioPharma (US).....II-88
Schering-Plough Corporation (US).....II-88
1$100
   Strategic Diagnostics Inc (US).....II-89
UCB Group (Belgium).....II-89
Wyeth Pharmaceuticals (US).....II-89
2$200
   Table 10: World Recent Past, Current & Future Market Analysis for Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-911$300
   Table 11: World Long-term Projections for Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-921$300
   Table 12: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-931$300
   Table 13: World Recent Past, Current & Future Market Analysis for Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-941$300
   Table 14: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-951$300
   Table 15: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-961$300
   Table 16: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment – Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-97

Table 17: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment – Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-97
1$300
   Table 18: World 10-Year Perspective for Therapeutic Monoclonal Antibody Based Products by Segments – Percentage Breakdown of Dollar Sales for Cancer and Other Therapeutics Markets for Years 2003, 2008 & 2012.....II-981$300
   Table 19: World Recent Past, Current & Future Market Analysis for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-991$300
   Table 20: World Long-term Projections for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1001$300
   Table 21: World 10-Year Perspective for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1011$300
   Table 22: World Recent Past, Current & Future Market Analysis for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-1021$300
   Table 23: World Long-term Projections for Other (*) Therapeutic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1031$300
   Table 24: World 10-Year Perspective for Other (*) Therapeutic Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1041$300
   Table 25: World Recent Past, Current & Future Market Analysis for Diagnostic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-1051$300
   Table 26: World Long-term Projections for Diagnostic Monoclonal Antibody Based Products by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1061$300
   Table 27: World 10-Year Perspective for Diagnostic Monoclonal Antibody Based Products by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1071$300
   A. Market Analysis.....III-1
Global Hub of MAbs.....III-1
Approved Therapeutic Antibodies in the US (as of 2007).....III-1
1$75
   Therapeutic Monoclonal Antibodies Market – An Overview.....III-2
New Heights for US Cancer Therapeutics.....III-2
Competitive Landscape.....III-2
1$75
   Leading Products.....III-3
Table 28: Leading Products in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Breakdown of Revenues for Remicade, Avastin, Rituxan, Herceptin, Synagis, Lucentis, Erbitux, and Others (includes corresponding Graph/Chart).....III-3
1$150
   Table 29: Leading Players in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Share Breakdown of Revenues for Genentech Inc, Centocor, MedImmune, Bristol Meyer's Squibb, Amgen, Hoffman-La Roche, and Others (includes corresponding Graph/Chart).....III-4
Focus on Key Players.....III-4
Amgen, Inc......III-4
1$150
   BD Biosciences.....III-5
Biogen Idec Inc.....III-5
1$75
   CMC ICOS Biologics, Inc......III-6
Dendreon Corporation.....III-6
1$75
   Eli Lilly and Company.....III-7
Genentech, Inc......III-7
Human Genome Sciences.....III-7
1$75
   Immunomedics.....III-81$75
   Johnson & Johnson.....III-9
Centocor.....III-9
Ortho Biotech Products, L.P......III-9
Medarex, Inc......III-9
1$75
   MedImmune, Inc.....III-101$75
   PDL BioPharma.....III-11
Schering-Plough Corporation.....III-11
Strategic Diagnostics Inc.....III-11
1$75
   Wyeth Pharmaceuticals.....III-12
Product launches.....III-12
2$150
   Strategic Developments.....III-1418$825
   B. Market Analytics.....III-32
Table 30: US Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-32
1$150
   Table 31: US Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-33

Table 32: US 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-33
1$150
   A. Market Analysis.....III-34
Strategic Developments.....III-34
1$75
   B. Market Analytics.....III-35
Table 33: Canadian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-35

Table 34: Canadian Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-35
1$150
   Table 35: Canadian 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-36
1$150
   A. Market Analysis.....III-37
Strategic Developments.....III-37
3$225
   B. Market Analytics.....III-40
Table 36: Japanese Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010, (includes corresponding Graph/Chart).....III-40

Table 37: Japanese Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-40
1$150
   Table 38: Japanese 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-41
1$150
   A. Market Analysis.....III-42
Biotechnology and Pharmacy Research.....III-42
Monoclonal Antibody-Based Products Market in Europe.....III-42
European Therapeutic MAbs Market – An Overview.....III-42
Approved Therapeutic Antibodies in Europe as of 2004.....III-42
1$75
   Need to Reduce Complexities, Time & Cost of mAb Development.....III-43
Information Dissemination – Critical for Enhancing mAb Sales.....III-43
Monoclonal Antibody Immunotherapy for NHL.....III-43
MabThera – A Dominant MAb Drug in Europe.....III-43
1$75
   Emerging Radioimmunotherapy Products.....III-44
Challenges for New Drug Development.....III-44
1$75
   B. Market Analytics.....III-45
Table 39: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Geographic Region – France, Germany, Italy, UK & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-45

Table 40: European Long-term Projections for Monoclonal Antibody Based Products by Geographic Region – France, Germany, Italy, UK & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-45
1$150
   Table 41: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-46

Table 42: European Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-46
1$150
   Table 43: European 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region –Percentage Breakdown of Dollar Sales for France, Germany, Italy, The UK, and Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-471$150
   Table 44: European 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-48
1$150
   A. Market Analysis.....III-49
Strategic Developments.....III-49
2$150
   B. Market Analytics.....III-51
Table 45: French Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-51

Table 46: French Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-51
1$150
   Table 47: French 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-52
1$150
   A. Market Analysis.....III-53
Biotest AG- A Key Player.....III-53
Product Launches.....III-53
1$75
   Strategic Developments.....III-542$150
   B. Market Analytics.....III-56
Table 48: German Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-56

Table 49: German Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-56
1$150
   Table 50: German 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-57
1$150
   Market Analysis.....III-58
Table 51: Italian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-58
1$150
   Table 52: Italian Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-591$150
   Table 53: Italian 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-60
1$150
   A. Market Analysis.....III-61
Monoclonal Antibodies Market – An Overview.....III-61
Strategic Developments.....III-61
2$150
   Product Launches.....III-631$75
   B. Market Analytics.....III-64
Table 54: UK Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment –Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-64

Table 55: UK Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-64
1$150
   Table 56: UK 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-65
1$150
   A. Market Analysis.....III-66
Key Players.....III-66
Elan Corporations Plc (Ireland).....III-66
UCB Group (Belgium).....III-66
1$75
   Strategic Developments.....III-673$225
   B. Market Analytics.....III-70
Table 57: Rest of Europe Market for Monoclonal Antibody Based Products – Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-70
1$150
   Table 58: Rest of Europe Long-term Projections for Monoclonal Antibody Based Products by Segment – Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-711$150
   Table 59: Rest of Europe 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-72
1$150
   A. Market Analysis.....III-73
Australia.....III-73
India.....III-73
Strategic Developments.....III-73
2$150
   B. Market Analytics.....III-75
Table 60: Rest of World Market for Monoclonal Antibody Based Products – Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-75

Table 61: Rest of World Market for Monoclonal Antibody Based Products – Long-term Projections by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-75
1$150
   Table 62: Rest of World 10-Year Perspective for Monoclonal Antibody Based Products by Segment – Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-761$150
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com